Discussion
Treatment with the approved oral med Fabhalta (iptacopan) helped maintain control of paroxysmal nocturnal hemoglobinuria (PNH) without any sudden, renewed destruction of red blood cells or new blood clots for five people in the U.S. with the rare disease — even during infections and while undergoing minimally invasive…